- Home
- AMAL vs ORKA Comparison
AMAL vs ORKA Comparison
Compare AMAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | ORKA |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Commercial Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.6M | 1.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMAL | ORKA |
|---|---|---|
| Price | $31.90 | $30.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $33.50 | ★ $45.22 |
| AVG Volume (30 Days) | 185.6K | ★ 412.0K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $306,936,000.00 | N/A |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | ★ 1.29 | N/A |
| 52 Week Low | $25.03 | $5.49 |
| 52 Week High | $37.26 | $32.28 |
Technical Indicators
Market Signals| Indicator | AMAL | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 70.62 | 57.21 |
| Support Level | $29.75 | $26.73 |
| Resistance Level | $32.48 | $32.28 |
| Average True Range (ATR) | 0.84 | 1.63 |
| MACD | 0.22 | -0.05 |
| Stochastic Oscillator | 89.69 | 68.21 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.